Market for Benign Prostatic Hyperplasia Treatment Market To Offer Lucrative Growth Prospects for Manufacturers : Fact.MR

The study on the benign prostatic hyperplasia (BPH) treatment market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that have been influencing the growth of the market. This exclusive study provides incisive insights regarding recent developments in the benign prostatic hyperplasia treatment market, by analysing the historical data for the period of 2017-2019, while the duration 2020-2027 is considered as the forecast period.

Evaluation of the benign prostatic hyperplasia treatment market's revenue has been calculated in terms of value (US$ Mn). This research provides information into the key trends that are potential enough to influence the growth of the benign prostatic hyperplasia treatment market.

For critical insights on this market, request for More Info - https://www.factmr.com/connectus/sample?flag=S&rep_id=4412

Besides this, the study also includes several macroeconomic and microeconomic growth indicators complementing growth of the BPH treatment market during the forecast period. This detailed study provides information into the key dynamics, and their influence on the benign prostatic hyperplasia treatment market during the forecast period.

The report also provides information into the key challenges and threats that could deter the growth potential of players in the benign prostatic hyperplasia treatment market.

The study unveils profitable opportunities for manufacturers, which they can adopt to strengthen their position in the global BPH treatment market. With a view of aiding stakeholders in the benign prostatic hyperplasia treatment market, the study comprises a detailed section on the competition analysis.

Benign Prostatic Hyperplasia Market - Assessment of Key Segments

Authors of this comprehensive study have classified the BPH treatment market into key segments for an in-depth study of the market. Categorisation of the benign prostatic hyperplasia treatment market is based on treatment type, end user, and region. This detailed study also offers information about the incremental opportunities present in the benign prostatic hyperplasia treatment market during the forecast period. Key segments considered while studying the benign prostatic hyperplasia treatment market include:

Treatment Type
Drug Classes
Alpha Blockers
5-Alpha-reductase Inhibitors (5-ARIs)
Phosphodiesterase-5 Enzyme Inhibitors
Others

Minimally-invasive Surgeries
Transurethral Resection of the Prostate (TURP)
Transurethral Incision of the Prostate (TUIP)
Robotic Surgeries
Transurethral Microwave Thermotherapy (TUMT)
Prostatic Urethral Lift
Others

Laser Therapy
Others
End User
Hospitals
Ambulatory Surgical Centres
Specialty Clinics
Others

Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Revenue of the benign prostatic hyperplasia treatment market has been estimated in terms of US$ Mn for the period of 2020 to 2027. In addition to this, compound annual growth rate (CAGR %) has been estimated for all segments during the forecast period 2020-2027, considering 2019 as the base year, in the benign prostatic hyperplasia treatment market.

Research analysts of the study on the benign prostatic hyperplasia treatment market have focused on leading, prominent, and emerging players, which include Olympus Corporation, Boston Scientific Corporation, LISA Laser, Teleflex Incorporated, Urologix, LLC, and Endo International PLC.

Request more information about Report Methodology - https://www.factmr.com/connectus/sample?flag=RM&rep_id=4412

Rise in Medical Tourism Catapulting Indian Benign Prostatic Hyperplasia Treatment Market

According to the Fact.MR study, the typical cost of transurethral resection of the prostate (TURP) in the U.S. ranges from US$ 8,000 to US$ 12,000, while cost of the same surgery in India is significantly lower (around US$ 1,500 to US$ 6,000). Cost benefits of TURP surgery in India are despite the use of cutting-edge technology and diagnostic equipment by surgeons for offering better patient outcomes.

This is creating a novel revenue stream for the benign prostatic hyperplasia treatment market through medical tourism, especially driven from patients from Western countries such as the U.S. and the U.K. Also, hospitals-both, private and public-are free from long waitlists, and India has also relaxed visa policies, which further turns the country favourable for medical tourism.

For in-depth competitive analysis, Buy Now - https://www.factmr.com/checkout/4412

Benign Prostatic Hyperplasia Market - Research Methodology

The primary objective of this exclusive study on the BPH treatment market is to offer precise estimates and forecasts of the market in terms of value (US$ Mn) for the period of 2020-2027. The secondary objective includes analysis of key market segments exhibiting significant growth rates, leading strategies adopted by players in the benign prostatic hyperplasia treatment market, and recalibrate the adoption rate of benign prostatic hyperplasia treatment in key regions across the world.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email : sales@factmr.com
Website : https://www.factmr.com

About Us:
Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.